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2-Allylisopropylacetamide, a porphyrinogen which 
decreases the microsomal and cytosolic heme pools, is 
a phenobarbitone-like inducer  of cytochrome P-45O(b + e) messenger RNAs in rat liver. The porphyrinogen, 
however, does not affect the nuclear heme pool and 
enhances the transcription of cytochrome P-450(b + e) 
messenger RNAs strikingly. Inhibitors of  heme biosyn- 
thesis, such as CoCL and 3-amino-1,2,4-triazole, 
which decrease the total heme levels including that of 
the nuclear heme pool, block the Z-allylisopropyla- 
cetamide- or phenobarbitone-mediated increase in the 
transcription of cytochrome P-450(b + e) messenger 
RNAs. Administration of exogenous heme at a very 
low concentration (25 pg/100 g)  is able to counteract 
the inhibitory effects of the heme biosynthetic inhibi- 
tors. Addition  of  heme in vitro to heme-depleted nuclei 
leads  to a significant increase in  the transcription rates 
for cytochrome P-45O(b + e) messenger RNAs. 2-A1- 
lylisopropylacetamide, unlike phenobarbitone, fails to 
increase the levels of cytochrome P-450b protein at 12 
h after the drug administration, although there is a 
striking increase in the messenger RNA levels. Under 
conditions of 2-allylisopropylacetamide treatment, the 
cytochrome P-450 messenger RNA is translated, but 
the newly synthesized apoprotein undergoes rapid deg- 
radation. It is concluded that heme is a positive modu- 
lator of cytochrome P-450 gene transcription and is 
also required to stabilize the freshly synthesized apo- 
protein. 
The hepatic cytochrome P-450 gene system constitutes  a 
multigene family, and the structure of prototype subfamilies 
is under intense investigation (1, 2). While the different 
subfamilies are activated by prototype chemicals such as 
phenobarbitone (PB),’ 3-methylcholanthrene, and pregneno- 
lone 16a-carbonitrile in the liver, it is also clear that a variety 
of other factors, small and large, are involved in the regulation 
of expression of these genes  (3-7).  One such factor implicated, 
arising out of studies in this laboratory, is heme (%lo),  the 
prosthetic group of cytochrome P-450. It has been shown that 
inhibitors of heme biosynthesis such as CoC12, 3-amino-1,2,4- 
triazole (AT),  and thioacetamide block the transcription of 
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PB-inducible cytochrome P-450(b + e) messenger RNAs in 
rat liver and consequently decrease the levels of the protein 
species. Based on this indirect evidence, it has been suggested 
that heme is perhaps  a positive modulator of cytochrome P- 
450  gene expression. 
Heme is a versatile regulatory molecule and is known to 
regulate a variety of cellular processes such as differentiation, 
transcription,  and  post-translational processing in different 
systems (11-14). It is thus of interest to examine the  site(s) 
of action of heme and provide direct evidence for its involve- 
ment in the regulation of cytochrome P-450(b + e) gene 
expression. For this purpose, first of all, the effects of 2- 
allylisopropylacetamide (AIA) on cytochrome P-450(b + e) 
messenger  RNA and protein synthesis have been compared 
with those of CoClz and AT in the present study. AIA is a 
porphyrinogen and is known to selectively degrade cyto- 
chrome P-450-heme and deplete the cytoplasmic heme pool 
as  a result of the hemeprotein acting  as  a sink (15, 16). CoC12 
depletes the total heme pool  by inhibiting  its  synthesis  and 
promoting its degradation. The effects of supplementing ex- 
ogenous heme under these conditions of heme depletion on 
cytochrome P-450(b + e) mRNA contents  and  their  transcrip- 
tion as well as on the apoprotein levels  have  been examined. 
MATERIALS AND METHODS 
Treatment of Animals-Male rats (80-90  g) of the Institute  strain 
were injected with PB (8 mg/100 g body  weight, intraperitoneally), 
CoC12.6H20 (6 mg/100 g, subcutaneously), AIA (30 mg/100 g, sub- 
cutaneously), AT (300  mg/100 g  intraperitoneally), and hemin (dis- 
solved in alkali and neutralized with Tris buffer, pH  8.0,25 pg-2  mg/ 
100 g, intraperitoneally) wherever indicated. In some experiments, 
the dose of PB was decreased to 2 mg/100  g. 
Labeling of Microsomal and Nuclear Heme Pools-To study the 
effect of AIA on the degradation of these heme pools, the animals 
first of all received 5 &i of [4-’4C]b-aminolevulinate as  the heme 
precursor. After 6 h, the animals received AIA or PB, and, after 
another  2  h, the animals were  killed. In  another set of experiments, 
the effects of CoC12 and AT on heme synthesis were examined by 
injecting the labeled precursor simultaneously with these compounds. 
The animals were killed after  4  h,  and the livers were processed. The 
microsomal and purified nuclear fractions were obtained by standard 
procedures as described earlier (8-10). The nuclei were additionally 
washed with buffered 0.25 M sucrose containing 1% (w/v) Triton X- 
100 to remove the outer membrane along with the endoplasmic 
reticulum contaminants. The heme fraction was isolated by the ethyl 
acetate/acetic acid extraction procedure (16). The ethyl  acetate layer 
was extracted with 1.5 N HCl to remove the porphyrins, thoroughly 
washed with water, and  then concentrated for radioactivity measure- 
ments. Separate chromatographic analysis revealed that  the entire 
radioactivity in the final  ethyl  acetate layer is only associated with 
heme. 
Cytochrome P-450(b + e)  mRNA Quantification-Poly(A)-contain- 
ing RNA was isolated from magnesium-precipitated polyribosomes 
using oligo(dT)-cellulose chromatography (17). Cytochrome P-450(b 
+ e) mRNA was quantified by dot-blot and Northern blot hybridi- 
zations (18) using nick-translated pP-450-91 DNA, a cloned probe 
isolated in this laboratory (8). Quantification of nuclear premessenger 
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RNA for cytochrome P-450(b + e) was also carried out as described 
by Ravishankar and Padmanaban (8). 
Nuclear Run-off Transcription-This was carried out essentially 
by the procedure of Guertin et al. (19) and has been described (8). 
Briefly, nuclei were isolated from control and drug-treated animal 
livers and incubated with 200 pCi of [a-32P]UTP  and other compo- 
nents including placental RNase  inhibitor in a total volume of 200 
pl. Incubation was carried out for 45 min at  25 “C. The labeled RNA 
transcribed was isolated by phenol/chloroform extraction  after pro- 
teinase K and DNase I treatments. pP-450-91 DNA  was linearized 
and loaded onto nitrocellulose filters, and hybridization was carried 
out with the labeled RNA transcripts. The hybridized radioactivity 
was measured after washing and pancreatic and TI RNase  treatments. 
a-Amanitin (1 pg/ml) was added to check for the specificity of mRNA 
hybridization with the cloned probe. Filters  containing pBR322 DNA 
served as blank controls. 
Cytochrome P-450(b + e) Protein Synthesis in Cell-free system- 
Cell-free protein synthesis was carried out in the reticulocyte system 
as well as in a homologous system using microsomes and  the SlOO 
fraction. The procedures have been described earlier (8-10, 20). The 
incubation mixture was solubilized and immunoprecipitated with the 
anti-cytochrome P-450b antibody, and  the immunoprecipitate was 
analyzed by SDS-PAGE (8% polyacrylamide) and autoradiography. 
The cytochrome P-450 band was cut  out of the gel and digested with 
Hz02, and radioactivity was measured. 
Effect of Drug Treatments on the Stability of Freshly Synthesized 
Cytochrome P-450& + e) Protein-The animals received AIA or PB, 
and, after  4  h, 100 pCi of [35S]methionine was injected intraperito- 
neally. After 30 min, cycloheximide (1 mg/100 g) was injected to 
block further  protein synthesis. The animals were killed 30 min and 
2 h after cycloheximide administration, cytochrome P-450(b + e) 
protein was immunoprecipitated from solubilized microsomes, and 
radioactivity was measured. Cycloheximide  was found to inhibit cy- 
tosolic protein synthesis by more than 95% at  the concentration and 
time intervals used in the study. 
Distribution of r‘C]PB in Vivo in the Presence and Absence of 
AZA-Phen0[2-’~C]barbitone (25 pCi) was injected into two sets of 
rats (50 g) intraperitoneally. One set received saline and  another AIA, 
15 min before the administration of the radioactive drug. The animals 
were killed after 4  h, and microsomal, cytosolic, and nuclear fractions 
were isolated from the Liver. The purified nuclear fraction was further 
fractionated into chromatin  extract (0.3 M NaCl) and insoluble chro- 
matin pellet. The distribution of radioactivity in all the fractions was 
measured. 
Other Procedures-Antibodies to purified cytochrome P-45Ob  were 
raised in  rabbits (8-10). Total cytochrome P-450 was estimated  in 
microsomal suspensions by the procedure of Omura and  Sat0 (21). 
Cytochrome P-45Ob protein was quantified by the radial immuno- 
diffusion procedure as described by Thomas et al. (22). 
RESULTS AND DISCUSSION 
First of all, it was of interest to compare the effects of AIA, 
CoC12, and A T  on the nuclear heme pool, since the porphy- 
rinogen is known to deplete microsomal and cytosolic heme, 
and  the  latter two chemicals are known inhibitors of heme 
biosynthesis. This was carried out as per the protocol de- 
scribed under “Materials  and Methods” and  Table I. Triton 
X-100 was  used to remove the outer membrane from purified 
nuclei and  the endoplasmic reticulum contamination of the 
nuclear preparation, based on cytochrome P-450 and cyto- 
chrome b6 estimations, could not have been more than 1%. 
The results presented in  Table I indicate that AIA adminis- 
tration decreases prelabeled microsomal heme by nearly 50% 
within 2 h. The labeled nuclear heme pool accounts for nearly 
5% of the microsomal heme pool on protein basis, but is not 
significantly affected by the porphyrinogen administration. 
PB administration does not affect the labeling of microsomal 
or nuclear heme pool under the experimental conditions em- 
ployed. The effects of CoClz and AT on microsomal and 
nuclear heme were studied in  separate experiments, where the 
radioactive precursor was injected along with the inhibitors. 
The results  presented  in  Table I indicate that CoClz and AT 
TABLE I 
Effect of AIA,  CoC1, and AT administration on the labeling of 
microsomal and nuclear heme pools 
The experimental details  are given in text. The  data given for AIA 
and  PB pertain to  their effects on prelabeled heme. The  data given 
for CoClz and A T  pertain to their effects on fresh heme synthesis 
and represent the mean obtained from two experiments. 
Radioactivity in heme 
fraction 
Nuclei Microsome 
Treatment 
cprnll0 mg protein 
Experiment I 
Control 610  18,095 
PB 660 
AIA 
16,178 
590  8,755 
Control 512  11,082 
COClZ 106  2,131 
AT 186  5.078 
Experiment I1 
TABLE I1 
Effect of saturating and suboptimal doses of PB and AIA on the 
induction of cytochrome P-450& + el  mRNAs 
PB (8 mg or 2 mg/100 g, intraperitoneally) and AIA (30 mg or 5 
mg/100  g, subcutaneously) were  given independently or together for 
12 h, and  the cytochrome P-450(b + e) mRNA concentration was 
estimated by dot-blot hybridization. Poly(A)-containing RNA (1 pg) 
was loaded on the filters. The data represent the mean f S.D. 
obtained from four exueriments. 
Treatment P-450(b + e) 
Cytochrome 
mRNA 
Saturating dose 
Control 
PB 
AIA 
PB + AIA 
Control 
PB 
AIA 
PB + AIA 
Suboptimal dose 
cpm  hybridized 
63 f 12 
1050 f 72 
972 f 51 
1123 f 96 
71 f 14 
483 f 27 
362 f 21 
910 f 43 
inhibit by 80% and 60%, respectively, the microsomal and 
nuclear heme labeling. 
The effects of  AIA, CoClZ, and AT on PB-mediated induc- 
tion of cytochrome P-450(b + e) mRNAs were then studied. 
A quantitative evaluation of the dot-blot hybridization data 
presented  in  Table I1 indicates that AIA does not affect the 
PB-mediated induction of cytochrome P-450(b + e) mRNA, 
but is actually a good inducer of these messenger RNAs by 
itself. Although saturating doses of PB and AIA  given together 
do not show inhibitory or additive effects, suboptimal doses 
when  given together show an additive effect. Earlier, Brooker 
et al. (23) have shown that AIA behaves as  a PB-like inducer 
in  the chick embryo liver system. The Northern blot (Fig. la)  
indicates that  PB and AIA induce cytochrome P-450(b + e) 
messenger RNA species with similar electrophoretic mobili- 
ties, and the size range works out to around 1800 k 100 
nucleotides. In addition, the blot also depicts the additive 
effects of PB and AIA when given at suboptimal doses. 
Administration of CoC1, and AT inhibits the PB- or AIA- 
mediated induction process (Fig. lb) .  These  inhibitors block 
the cytochrome P-450(b + e) nuclear premessenger RNA 
induction by  AIA (Fig. IC). Similar results with PB have  been 
reported earlier (8). 
The nuclear run-off transcription experiments reveal that 
AIA, like PB, enhances the transcription of cytochrome P- 
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FIG. 1. Effect  of PB, AIA, and  inhibitors of heme biosyn- 
thesis on the induction of cytochrome P-4SO(b + e) mRNAs. 
a, Northern blot analysis of poly(A)-containing RNA isolated 12 h 
after PB  or AIA treatments. Poly(A)-containing RNA (20 pg) was 
run  on agarose/formaldehyde gels. 1, control; 2, (PB + AIA)-treated; 
3, PB-treated; 4, AIA-treated. All the drugs were  given at  suboptimal 
doses. b, dot-blot analysis of poly(A)-containing RNAs. The animals 
were  given drug treatments for 6 h, and 1 pg of RNA  was loaded on 
nitrocellulose filters. T 1, control (42); 2, PB (655); 3, PB + CoCl, 
(157); B: 1, AIA (553); 2, AIA + CoC12 (55); 3, AIA + AT (95). The 
radioactivity (cpm) in the dots is given in parentheses. e, dot-blot 
analysis of nuclear RNA. Total nuclear RNA (10 pg)  was loaded on 
the filters. 1, control; 2, AIA; 3, AIA + CoCI2; 4, AIA + AT. 
450(b + e) mRNAs and CoC12 or AT administration blocks 
this effect (Table 111). It is clear that  PB and AIA induce the 
same or very  closely related cytochrome  P-450 mRNA species 
and both drugs act at  the level of transcription. In view of 
these results and  the  data that  at subsaturating levels the two 
drugs show an additive effect on cytochrome P-450(b + e) 
mRNA induction (Table 11, Fig. la), the possibility of the 
presence of common or identical intracellular binding sites 
for the two drugs was examined. The results presented in 
Table IV indicate that, in presence of cold AIA, there is a 
significant decrease in the localization of pheno(2-14C]barbi- 
tone in the microsomal fraction and  the 0.3 M NaCl extract 
of the chromatin. Under these conditions, the  total uptake of 
the labeled  drug into  the liver  is not affected and  there is an 
increase in the cytosolic  radioactivity. The competition be- 
tween the two drugs at the microsomal  level  is perhaps due 
TABLE I11 
Effect of PB, AZA, CoCI, and AT on the transcription of cytochrome 
P-450@ + e) mRNA with isolated  nuclei 
Nuclei were isolated from animals given 12 h of drug  treatment. 
The total RNA transcripts used for hybridization were adjusted to 
provide lo7 cpm of radioactivity. There was no significant difference 
in total RNA transcription in any of the treatment conditions. 
Inclusion of a-amanitin (1 pg/ml) in the incubation mixture inhibited 
total RNA transcription by about 50%. Cytochrome P-450(b + e) 
mRNA was inhibited by about 96%. pBR322 DNA-loaded filters 
served as blank controls. The  data obtained from two independent 
experiments are given and  are expressed in terms of parts per million 
of RNA transcripts hybridized. 
Cytochrome P-450 
(b + e) mRNA 
Treatment transcription 
I I1 
ppmlkilobme pairs 
cloned probe 
Control 6 8 
PB 145 167 
AIA 152 146 
PB + AT 46 60 
AIA + AT 52 46 
PB + COCIZ 33 25 
AIA + COCI~ 25  21 
TABLE IV 
Eflect of AZA on ["CJPB distribution in different cellular fractions 
Phen0[2-"C]barbitone (25 pCi) was injected into rata (50-60 g) 
that had received saline or AIA, 15 min before the administration of 
the label. The animals were  killed after 4 h, livers from two animals 
were  pooled, and the radioactivity distribution in the different cellular 
fractions was examined. The  data obtained from two independent 
experiments are given. 
Radioactivity 
Fraction -AIA +AIA 
I I1 I I1 
cpmlmg  protein 
Homogenate 2493 2635 2669 2915 
Cytosol 3827 4007 5045 5401 
Microsomes 1692 1758 915 1005 
Chromatin extract 719 773 315 381 
Chromatin pellet 33 39 30 40 
to competition for binding to the same cytochrome P-450 
species. The competition in the 0.3 M NaCl extract of the 
chromatin may be indicative of a common receptor for the 
two  drugs. This aspect needs further study, since the identi- 
fication of a receptor  for PB has remained elusive (24,25). 
These results clearly establish that AIA, which  competes 
for PB binding sites in the microsome and nucleus, is a typical 
PB-like inducer of cytochrome  P-450 mRNAs.  However,  while 
PB does not affect the heme  pools at  least at early  periods of 
drug action, AIA depletes the microsomal and cytosolic  heme 
pool without significantly affecting the nuclear heme  pool. In 
order to provide direct proof that heme regulates  cytochrome 
P-450(b + e) mRNA transcription and that the nuclear  heme 
pool may influence these transcription rates, the following 
experiments were carried out. First of all, the ability of  exog- 
enously administered heme (hematin) to counteract the in- 
hibitory effects of  CoCI, on PB-mediated induction of cyto- 
chrome P-450(b + e) mRNAs  was  examined. In preliminary 
experiments, it was found that heme  in  doses ranging from 
25 pg/100 g to 2 mg/100 g was not able to counteract the 
effects of  CoCl, in this regard (data not presented). However, 
in parallel expriments, it was found that heme at  as low a 
concentration as 50 pg/100 g was able to counteract the 
(0.3 M NaCI) 
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FIG. 2. Effect of  exogenous hemin on CoClz-mediated inhi- 
bition of cytochrome P-450(b + e) mRNA induction by subop- 
timal doses of phenobarbitone. The animals were  killed 12 h  after 
the drug treatments and 20 pg of total polyribosomal  RNA  was  loaded 
on the filters. T: 1 ,  control (134); 2, PB (712); 3, PB + CoCI2 (176); 
B :  1, PB + CoC12 + hemin, 25 pg (650); 2, PB + CoC12 + hemin, 50 
pg (353); 3, PB + CoCI2 + hemin, 100 pg (186). The radioactivity 
(cpm) in the dots is given in parentheses. 
inhibitory effects of  CoC12 on 3-methylcholanthrene-mediated 
induction of cytochrome P-450(c + d) mRNAs.* Therefore, it  
was felt that  the failure of exogenous heme to counteract the 
effects of CoC12 in the case of PB-mediated induction of 
cytochrome P-450(b + e) mRNAs could perhaps be due to  PB 
inhibiting heme uptake into  the regulatory heme pools. Such 
a competition at  the intracellular level for microsomal local- 
ization was noticed by Marver (26). Therefore,  in the present 
study, the heme reversal experiments were carried out a t  a 
lower PB concentration of 2 mg/100 g body weight. The 
results  presented in Fig. 2  indicate that,  at  this concentration, 
phenobarbitone induces cytochrome P-450(b + e) mRNAs by 
5-fold. The interesting  result is that heme at  as low a concen- 
tration  as 25 pg/100 g body weight is now able to counteract 
the inhibitory effects of CoC1,. Surprisingly, when the heme 
concentration is increased to 100 pg/100 g body weight, the 
counteracting  potential is lost. The reasons for this intriguing 
concentration-dependent  action of heme are  not clear. I t  may 
be that  the size of the regulatory heme pool is strictly modu- 
lated and  the presence of  CoCl, together  with  a  slight excess 
of exogenous heme perhaps promotes degradation as well as 
inhibition of synthesis of the regulatory heme pool. In  any 
case, the results clearly establish that heme is a positive 
modulator of cytochrome P-450(b + e) mRNA transcription. 
In order to examine whether the nuclear heme pool regu- 
lates cytochrome P-450(b + e) mRNA transcription, run-off 
transcription  experiments were carried out in presence and 
heme added in uitm to heme-depleted nuclei. The results 
presented  in Table V indicate that heme, when added a t  a 
concentration of  10" M to nuclei isolated from (PB + CoC12)- 
treated animals, is able to increase cytochrome P-450(b + e) 
mRNA transcription rates  to  as much as 60% of the maximal 
transcription rates obtained  with nuclei from PB-treated  an- 
imals. Heme, when added a t  concentrations of M or lo" 
M, is only marginally effective. Further studies are needed to 
study the effects of a closer range of heme concentrations. 
While these  results lend evidence to the suggestion that  the 
nuclear heme pool does regulate cytochrome P-450(b + e) 
mRNA transcription, they also raise an intriguing  point for 
consideration. In these run-off nuclear transcription experi- 
ments, there is very little fresh  initiation. The fact that in 
uitro addition of heme is able to enhance significantly cyto- 
chrome P-450(b + e) mRNA transcription rates when added 
to heme-depleted nuclei would indicate that heme may (also) 
be acting at  downstream sites after initiation, as well as 
G. J. Bhat and G. Padmanaban,  unpublished data. 
TABLE V
Effect hemin addition in vitro to heme-depleted nuclei on run-off 
transcription of cytochrome P-450(b + e) mRNAs 
The experimental details are given  in text.  The results represent 
the mean f S.D. obtained from  three  independent experiments. 
Nuclei Cytochrome P-450(b + e) mRNA transcription 
ppmlkilobase pairs cloned probe 
Control 
PB (6 h) 
8 f 2  
135 f 10 
PB + CoCI2 + hemin (in  vitro) 
31 f 4  
44 f 5 
PB + CoC12 + hemin (in vitro) 88f6 
PB + CoC12 + hemin (in vitro) 53 f 9 
PB + hemin (in vitro) (IO" M) 128 f 11 
PB + hemin (in  vitro) (10" M) 109 f 8 
PB + CoC12 (6 h) 
(10-7 M) 
(10" M) 
M) 
TABLE IV 
Effect of exogenous hemin administration on the effects of Cock and 
AIA on cytochrome P-450b  protein levels 
Cytochrome P-450b was  quantified by  radial  immunodiffusion. The 
animals were  killed 12 h after the drug treatments. 
Treatment Cytochrome P-450b 
nnwllmg protein 
Control 0.03 
PB 0.59 
PB + CoCI2 + hemin (25 pg) 0.49 
AIA 0.09 
AIA + hemin (25 pg) 0.11 
PB + CoC12 0.09 
influencing RNA processing and stabilization  in the nucleus. 
The ability of  AIA to selectively degrade cytochrome P-450 
heme and to induce cytochrome P-450(b + e) mRNA has 
given us an opportunity to examine the role of heme in 
cytochrome P-450 protein synthesis. The results  on the radial 
immunodiffusion assay to quantify the cytochrome P-450b 
protein are presented in Table VI. It is interesting to note 
that PB enhances the cytochrome P-450b protein content 
significantly in 12 h. However, AIA which, like phenobarbi- 
tone, induces cytochrome P-450(b + e) mRNA, fails to in- 
crease cytochrome P-450b protein levels substantially. There- 
fore, the possible role of heme in the  translation of cytochrome 
P-450(b + e) mRNA was examined. Poly(A)-containing RNA 
isolated from the drug-treated rats was translated in the 
reticulocyte lysate cell-free system, and  the cytochrome P- 
450b synthesized was quantified by immunoprecipitation and 
estimation of radioactivity in the protein band after electro- 
phoresis. The same experiment was also carried out in ho- 
mologous cell-free systems, where protein  synthesis was car- 
ried out with microsomes and SlOO fraction isolated from the 
drug-treated  rats. The results  presented  in  Table VI1 indicate 
that both in  the homologous as well as heterologous cell-free 
systems, cytochrome P-450b was synthesized in equivalent 
quantities  under  conditions of PB  and AIA treatments.  These 
results  indicate that  the cytochrome P-450b mRNA induced 
by PB or AIA is translatable, and lack of heme or any tissue- 
specific factor is not responsible for the failure of the  latter 
drug to induce cytochrome P-450b protein at  the time period 
examined. Therefore, the possibility that  the freshly synthe- 
sized cytochrome P-450b apoprotein may undergo degradation 
in uiuo under  conditions of  AIA treatment due to lack of heme 
was examined. The results  presented  in Fig. 3 indicate that, 
in  the case of PB  treatment, freshly labeled cytochrome P- 
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TABLE VI1 
Effect of PB and AZA on  cytochrome P-450b protein synthesis in 
heterologous and homologous cell-free translation systems 
Poly(A)-containing RNA (8 pg) from PB- or AIA-treated (12 h) 
rats was translated  in the reticulocyte lysate cell-free system in the 
presence of [%]methionine (50 pCi) in a total volume of 100 pl. In 
the homologous cell-free system, microsomes from PB- or AIA- 
treated (12 h)  rats were incubated with the respective SlOO fraction 
in the presence of 50 pci ob [36S]methionine and other components 
in a total volume of 250 pl. After incubation, cytochrome P-45Ob was 
immunoprecipitated, and  the precipitate was analyzed on SDS-PAGE 
(8% gels). The cytochrome P-450 band was cut and digested with 
H202,  and radioactivity was measured. 
Treatment Total  protein Cytochrome P-450b synthesized  synthesized 
w m  % total 
Reticulocyte lysate 
Control 8.8 X 10’ 0.04 
PB 9.0 x 106 0.71 
AIA 8.8 X lo6 0.82 
Control 2.0 x lo6 0.07 
PB 1.8 X 10‘ 1.20 
AIA 2.1 x 108 1.13 
Microsomal system 
- Y 0.1 I 1 2 
Time (hr) 
FIG. 3. Effect  of PB and AIA on the degradation of  freshly 
synthesized  cytochrome P-45Ob protein. The experimental de- 
tails  are given in text. The immunoprecipitable radioactivity due to 
prelabeled cytochrome P-45Ob was measured after blocking fresh 
protein synthesis. 0, PB; A, AIA. 
450b is quite  stable  and  there  is  about 10%loss of radioactivity 
in about 2 h, when continued protein  synthesis is blocked  by 
cycloheximide.  However, under conditions of AIA treatment, 
there is massive degradation of freshly synthesized cyto- 
chrome P-450b protein. 
Exogenous administration of heme fails to counteract the 
inability of  AIA to enhance cytochrome P-450b protein levels. 
At the same time, exogenous heme is able to counteract the 
inhibitory effects of CoClz on PB-mediated induction of cy- 
tochrome P-450b protein  (Table VI). It is possible that exog- 
enously administered heme also undergoes degradation during 
AIA treatment by getting incorporated into cytochrome P- 
450, just  as is the case with cytosolic heme (16). Thus, while 
depletion of heme brought by  AIA is probably responsible for 
the degradation of the freshly synthesized apocytochrome P- 
450b, the possibility of the drug or its metabolite having a 
direct effect on the degradation of this  protein  cannot be ruled 
out. 
In summary, the results of the present investigation clearly 
establish that heme is a positive modulator of cytochrome P- 
450(b + e) mRNA transcription  and/or the immediate events 
following transcription initiation. The nuclear heme pool 
appears to influence this rate of transcription. Heme also 
appears necessary to stabilize the freshly synthesized cyto- 
chrome P-450 protein in response to PB. 
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